Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response

Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype with low overall survival rates and high molecular heterogeneity; therefore, few targeted therapies are available. The luminal androgen receptor (LAR) is the most consistently identified TNBC subtype, but the clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, Kevin J, Leon-Ferre, Roberto A, Sinnwell, Jason P, Zahrieh, David M, Suman, Vera J, Metzger, Filho Otto, Asad, Sarah, Stover, Daniel G, Carey, Lisa, Sikov, William M, Ingle, James N, Liu, Minetta C, Carter, Jodi M, Klee, Eric W, Weinshilboum, Richard M, Boughey, Judy C, Wang, Liewei, Couch, Fergus J, Goetz, Matthew P, Kalari, Krishna R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Cancer Computational Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204893/
https://www.ncbi.nlm.nih.gov/pubmed/35734391
http://dx.doi.org/10.1093/narcan/zcac018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204893/
https://www.ncbi.nlm.nih.gov/pubmed/35734391
http://dx.doi.org/10.1093/narcan/zcac018

Ejemplares similares